OTC:ZVSA
ZyVersa Therapeutics, Inc.
A biotech firm targeting rare disease treatments that recently secured $6M in financing while burning through cash at -$7.6M annually.
Key Metrics
Investment Thesis
Bull Case
Early-stage biotech investors may see ZyVersa as a high-risk, high-reward opportunity if their rare disease therapies achieve clinical approval and regulatory milestones. The company's significant long-term assets suggest strong underlying intellectual property that could yield substantial value upon commercialization. Recent financing efforts of $6M demonstrate active engagement with capital markets to sustain development until revenue generation begins.
Bear Case
With zero revenue and a massive accumulated deficit, ZyVersa poses an extreme risk of insolvency if it cannot secure further equity or debt financing in the near term. The cash burn rate is unsustainable without product sales, and the current liabilities significantly outweigh working capital reserves. Investors face total capital loss potential as there is no dividend history or profit track record to support valuation.
About ZyVersa Therapeutics, Inc.
ZyVersa Therapeutics is a biotechnology company focused on developing novel therapies for rare diseases, primarily operating within the United States. The company currently has no revenue but maintains significant long-term assets likely tied to intellectual property and research facilities. Its financial profile reflects a typical pre-commercialization stage with heavy reliance on financing cash flows to fund operations.
Analysis
Management Discussion
ZyVersa reported a net loss of -$9.4M for the latest year, driven by $7.4M in general and administrative expenses and $1.8M in research and development costs. Despite these operational losses, the company managed to increase its cash position through financing activities, though ending cash dropped from $3.1M to $1.5M due to the net change of -$1.6M.
Industry Overview
The biotechnology sector for rare diseases often requires substantial upfront investment with long development timelines before any revenue recognition occurs. Companies in this space typically experience significant volatility and rely heavily on grant funding, partnerships, or public markets for liquidity. Success depends entirely on navigating complex regulatory pathways and proving clinical efficacy to attract major pharma partners.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | — | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | — | $0 | $0 |
| Operating Expenses | — | $107.8M | $9.1M |
| Operating Income | — | $-107.8M | $-9.1M |
| R&D | — | $3.2M | $1.8M |
| G&A | — | $11.2M | $7.4M |
| Stock-Based Comp | — | $1.2M | $705.6K |
| Depreciation | — | $10.4K | $6.9K |
| Other OpEx | — | $93.3M | $0 |
| Non-Operating Income | $0 | $457 | $-269.9K |
| Pre-Tax Income | — | $-107.8M | $-9.4M |
| Income Tax | — | $-9.5M | $6.7K |
| Continuing Ops | — | $-98.3M | $-9.4M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | — | $-98.3M | $-9.4M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | — | $-98.3M | $-9.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $6.4M | $3.4M | $1.7M |
| Prepaid Expenses | — | $215.5K | $184.9K |
| Other Current Assets | — | $3.1M | $1.5M |
| Long-Term Assets | $112.1M | $18.8M | $18.9M |
| PP&E (Net) | $17.3K | $6.9K | — |
| Goodwill | $11.9M | — | — |
| Operating Leases | $98.4K | $7.8K | — |
| Other LT Assets | $100.1M | $18.7M | — |
| Total Assets | $118.5M | $22.1M | $20.6M |
| Current Liabilities | $8.2M | $10.2M | $11.2M |
| Accounts Payable | $6.0M | $8.4M | $9.3M |
| Current Leases | $108.8K | $8.7K | — |
| Other Current Liab | $0 | $0 | $0 |
| Long-Term Liabilities | $10.3M | $844.9K | $851.7K |
| Total Liabilities | $18.5M | $11.0M | $12.1M |
| Shareholders' Equity | $99.7M | $11.1M | $8.5M |
| Paid-In Capital | $104.6M | $114.3M | $121.2M |
| Retained Earnings | $-4.9M | $-103.2M | $-112.6M |
| Treasury Stock | — | $7.2K | $7.2K |
| Total L&E | $118.5M | $22.1M | $20.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | — | $-98.3M | $-9.4M |
| Non-Cash Adjustments | — | $87.2M | $1.0M |
| Working Capital Changes | — | $2.4M | $850.8K |
| Cash from Operations | — | $-8.7M | $-7.6M |
| Cash from Investing | — | $0 | $0 |
| Cash from Financing | — | $6.0M | $6.0M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | — | $-2.8M | $-1.6M |
| Beginning Cash | — | $5.9M | $3.1M |
| Ending Cash | $5.9M | $3.1M | $1.5M |
Frequently Asked Questions
How does ZyVersa Therapeutics, Inc. make money?
The company operates within the biotechnology sector with no current revenue streams, relying entirely on research and development initiatives for future product commercialization. Financials indicate a singular focus on drug discovery and clinical trials rather than diversified product sales or licensing agreements at this stage.
What are the main risks for ZVSA?
The company carries a substantial retained earnings deficit of -$112.6M and operates with negative cash flow from operations of -$7.6M, indicating high burn rates typical but risky for pre-revenue firms. Current liabilities exceed current assets by nearly $10M, creating potential liquidity pressure if financing dries up. There is a complete lack of revenue generation, making the business entirely dependent on future clinical trial successes and external funding.
What is ZVSA's competitive advantage?
ZyVersa leverages specialized expertise in rare disease mechanisms to navigate less saturated therapeutic areas with potentially lower competition. The company holds significant long-term assets of $18.9M, suggesting a robust intellectual property portfolio and established research infrastructure. Access to capital markets is critical, evidenced by recent common share issuances totaling $1.4M alongside substantial paid-in capital.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.